Human papillomavirus genotype distribution in tonsil cancers. by St Guily, Jean, et al.
Human papillomavirus genotype distribution in tonsil
cancers.
Jean St Guily, Christine Clavel, Claire Oka¨ıs, Jean-Luc Pre´tet, Agne`s
Beby-Defaux, Ge´rard Agius, Philippe Birembaut, Anne-Carole Jacquard,
Yann Le´ocmach, Benoˆıt Soubeyrand, et al.
To cite this version:
Jean St Guily, Christine Clavel, Claire Oka¨ıs, Jean-Luc Pre´tet, Agne`s Beby-Defaux, et al..
Human papillomavirus genotype distribution in tonsil cancers.. Head and Neck Oncology,
BioMed Central, 2011, 3 (1), pp.6. <10.1186/1758-3284-3-6>. <inserm-00617215>
HAL Id: inserm-00617215
http://www.hal.inserm.fr/inserm-00617215
Submitted on 26 Aug 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH Open Access
Human papillomavirus genotype distribution in
tonsil cancers
Jean Lacau St Guily1*, Christine Clavel2, Claire Okaïs3, Jean-Luc Prétet4, Agnès Beby-Defaux5, Gérard Agius5,
Philippe Birembaut2, Anne-Carole Jacquard3, Yann Léocmach3, Benoît Soubeyrand3, Didier Riethmuller4,6,
François Denis7, Christiane Mougin4
Abstract
Background: The incidence of tonsil cancers has increased in several countries. French data on HPV prevalence in
tonsil cancers are scarce. The objective of this study was thus to assess the overall and type specific HPV
prevalence in tonsil histological samples.
Methods: This French retrospective multicenter study involved 12 centres located throughout the country. Were
included 185 histological samples collected from year 2000 to 2009 with a validated diagnosis of tonsil invasive
carcinomas. HPV prevalence was studied according to gender, age and histological type of cancer.
Results: Overall HPV prevalence was 57% in tonsil cancers. Mean age of diagnosis was comparable in HPV positive
tonsils cases (60 ± 11.2) and HPV negative tonsil cases (59 ± 9.6). HPV prevalence was significantly higher in female
than in male cases (28/35 versus 78/150 in tonsil cases, respectively, P = 0.003). About 53% of tonsil cases were
infected by a single HPV type. Only eight (4%) samples were infected by more than one HPV type. Among HPV
positive samples, HPV 16 was found in 89% of tonsil cases. All other HPV types had prevalence below 5%.
Conclusions: Our results indicate that HPV is common in tonsil carcinomas and emphasize the predominant role
of HPV 16.
Background
Head and neck cancers (HNC) are the fifth most com-
mon cancer worldwide with more than 600,000 cases
diagnosed each year [1]. France is the country the most
affected by HNC in Europe with more than 16,000 new
cases in 2005 and 5,400 deaths. More cases are diag-
nosed in males than in females [2]. They are almost
exclusively head and neck (HN) squamous cell carcino-
mas (SCC), observed in different anatomical sites: oral
cavity, oropharynx, hypopharynx, and larynx [3]. Tonsil
cancer incidence was estimated to be more than 1,700
in France in 2004 [4].
The overall incidence of HNC has fallen in recent
years. This seems to be consistent with the decrease in
tobacco and alcohol consumption. By contrast, the inci-
dence of cancers in particular anatomical sites has
increased [3]. The incidence of oropharyngeal tumours
rose in the USA by 1.3% for base of tongue cancers and
by 0.6% for tonsil cancers every year between 1973 and
2004 [5]. Tonsil squamous cell carcinomas (SCC) in the
Stockholm area rose from 0.74/100,000 person-years in
1970-1979 to 1.65/100,000 person-years in 2000-2006
[6]. The age-adjusted incidence of tonsil cancer
increased 3.5-fold in women and 2.6-fold in men
between 1970 and 2002 in Sweden [7].
Well known main risk factors for developing orophar-
yngeal cancer are tobacco usage and alcohol consump-
tion [3]. Socio-economic deprivation [8] and poor oral
health [9] have also been reported. However a new pro-
file of patients suffering from HNSCC is emerging.
A better survival of patients with HPV positive HNSCC
is observed [10]. An increase of oropharyngeal SCC in
individuals with no history of tobacco or alcohol use has
been described [3]. New risk factors such as sexual
behaviors in HPV positive cancers are observed [11].
Different authors reported the presence of HPV in
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oropharyngeal tumors, especially in the lingual and
palatine tonsils [3,6]. Augmented incidence of HPV-
associated tonsil cancers seems to represent an emer-
ging public health problem.
French data on HPV prevalence in tonsil cancers are
scarce. The objective of this study was thus to assess the
overall and type specific HPV prevalence in tonsil histo-
logical samples.
Methods
Study design
The overall study which involved oropharyngeal and
oral cavity invasive cancers is described elsewhere. We
present here results of a substudy focused on tonsil
cancers. This French retrospective multicenter study
involved 12 centres located throughout the country.
Selection of the centres was mainly based on their will-
ingness to participate trying to get most French geogra-
phical areas represented. To be included, histological
samples had to be collected after year 2000. Each sample
with a validated diagnosis of tonsil cancers and fixed in
4% buffered formalin before paraffin embedding were
retrospectively included. Cases with diagnosis other than
SCC were excluded. Each centre decided whether its
own cases could be included. Patient data such as age at
diagnosis, gender, area of residence, year of sample col-
lection were collected for each case when available.
According to the French legislation (Public Health
Code modified by the law n° 2004-806, August 9, 2004
and the Huriet-Sérusclat act 88-1138, December 20,
1988) and since this study only involved data extracted
from medical records and stored histological specimens,
no informed consent from the patients was necessary.
Data collected from participating pathology centres were
strictly anonymous.
HPV genotyping
HPV genotyping was centrally performed using the
INNO-LiPA HPV Genotyping extra test (Innogenetics
Inc, Gent, Belgium). This kit allows the detection of
28 HPV types, 15 high-risk (HR) and 13 low-risk (LR)
[12]. In order to be consistent with previous EDiTH stu-
dies [13,14] the 28 HPV genotypes identified by the
INNO-LiPA assay were classified as follows: LR HPV:
genotypes 6, 11, 26, 40, 43, 44, 53, 54, 66, 70, 71, 73 and
74; HR HPV: genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 69 and 82
Statistical analysis
The HPV genotype-specific prevalence was expressed as
the proportion of HPV-positive samples among all carci-
noma cases and among HPV positive cases. HPV preva-
lence was studied according to gender, age and
histological type of cancer. Prevalence of HR and LR
HPV was also calculated. Categorical variables were stu-
died using 2-sided Chi-square or Fisher exact test when
necessary. All statistical analyses were performed using
SPSS v.11.5 for Windows. A p-value below 0.05 was
considered as statistically significant.
Results
A total of 220 of histological samples of tonsil invasive
SCC were retrospectively collected from 12 French pathol-
ogy centres scattered throughout the country. Patients
were recruited throughout France: 28% in Paris area, 8%
in the West area, 35% in the North and North East, and
28% in the South of France. 84% (185/220) were included
in the study while 16% (35/220) were excluded from the
analysis because neither HPV nor cellular DNA could
have been amplified. Mean age at diagnosis was 60 ± 10.5
years. There were 81% (150/185) of males.
We found an overall HPV prevalence of 57% (106/
185). Mean age of diagnosis was comparable in HPV
positive tonsil cancer cases (60 ± 11.2) and HPV nega-
tive tonsil cancer cases (59 ± 9.6). HPV prevalence was
higher in female than in male cases (80% (28/35) versus
52% (78/150) respectively, p = 0.003). About 53% (98/
185) of tonsil cancer cases were infected by a single
HPV type. Only 4% (8/185) of tonsil samples were
infected by more than one HPV type, with at least one
HPV HR. HPV 16 was found in 89% (94/106) of HPV
positive tonsil cases. All other HPV types had prevalence
below 5%. HPV 16 and/or 18 was found in 91% (96/106)
of HPV-positive tonsil cases. (Figure 1) Year of sample
varied from 2000 to 2009 (median of 2005) with no
clear variation of the percentage of HPV-positive tonsil
cancers with time.
Discussion
HPV has been suggested to be associated with approxi-
mately 25% of HNSCC. HPV has been identified in the
oropharynx and particularly in tonsil cancers in the
Figure 1 HR HPV distribution among tonsil HPV positive cases
(n = 106).
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literature [3,15]. Our study of 185 cases of tonsil SCC is
among the largest European patient series presented with
HPV analyses [16]. Tonsil cancers had a high prevalence
positivity (57%) and a very low HPV-HPV multiple infec-
tion proportion (4%) compared with carcinomas from all
other location within the head and neck region (data not
shown) which agrees with previous studies [16,17]. Han-
nisdal et al identified the HPV in 52% (71/137) of patients
with tonsil carcinomas from 1960 until 1996 in Norway
[17]. Syrjanen et al found in their review that 51% of the
432 tonsil cancers were HPV-positive, and less than 5%
were infected by multiple types of HPV [16]. Mellin et al
showed from 1984 to 1996 that HPV was present in 43%
(23/60) of tonsil cancers [18]. HPV was identified in 46%
of patients with tonsil SCC (24/52) from 1987 to 1995 in
the USA [19]. Inversely Li et al did not identify HPV in 16
tonsil cancer specimens from Chinese patients [20]
whereas the positivity rate was 46% in Australian patients
using the same methodology [21]. Chien et al found the
HPV in 13% (14/111) of the patients with tonsil carcino-
mas in Taiwan from 1992 to 2005 [22]. The discrepancy
in HPV prevalence could be partly explained by sample
sizes, by the methods used to determine HPV prevalence
(specimen type, method and duration of sample storage,
HPV detection procedure), by the fact that HPV-positive
cancers seem to increase during the last decades and by
epidemiological and lifestyle differences, such as alcohol
and tobacco consumption or sexual behavior.
Some authors found that the proportion of HPV posi-
tive tonsil SCC increased during the last decades. The
proportion of HPV cancers in the county of Stockholm,
using the same diagnostic method, was 23% (7/30) in the
1970s, 29% (12/42) in the 1980s, 57% (48/84) in the
1990s and 68% (32/47) in 2000-2002 [7] and 85% in
2003-2007 [6]. Hannisdal et al found that HPV positivity
was significantly more frequent (64%) in the latter period
(1985-1996) of the patient series compared with 38% in
the first period (1960-1985) [17]. We did not observe any
variation during the study but our study period was too
short to demonstrate any evolution with time.
HPV 16 was the genotype the most identified in the lit-
erature, 93% (77/83) of HPV-positive cases in the series
of Nasman et al 2003-2007 [6]. As for the review of Syrja-
nen, HPV 16 had been identified in 84% of the 216 HPV
DNA positive tonsillar SCCs [16]. Consistently with these
data, we found in our study that HPV 16 was present in
89% of all HPV-positive tonsil cancers. Interestingly, a
meta-analysis stratified by anatomical site suggested that
the association between HPV 16 and cancer was stron-
gest for tonsil (OR 15.1 [6.8-33.7), intermediate for oro-
pharynx (OR 4.3 [2.1-8.9]) and weakest for oral (OR 2.0
[1.2-3.4]) and larynx (OR 2.0 [1.0-4.2]) [23].
In our series, HPV prevalence was higher in female than
in male cases (80% versus 52%) even if men accounted for
the majority (81%) of the total tonsil cancers, which was
concordant with some studies. Nasman et al found that
HPV was present in 95% (21/22) of women cases of tonsil
cancers and in 82% (62/76) of men cases of tonsil cancers
[6]. HPV was identified in 65% of women cases (11/17)
and in 35% (15/43) of men cases in Sweden [18]. Chien et
al also noted that the greatest incidence of HPV-positivity
was associated with females (p < 0.001, odds ratio = 18.48,
95% CI = 5.55-61.51) [22]. Risk factors for HPV positive
and negative HNC such as sexual behavior for HPV posi-
tive tumors and tobacco and alcohol for HPV negative
tumors were clearly identified in various studies [3,11].
Thus, the higher proportion of HPV observed in women
cases could possibly result from a different risk factor dis-
tribution between men and women since smoking and
alcohol consumption are known to be more frequent in
men [24]. However, these points cannot be addressed in
our study since data were extracted from pathology
records and we had no patient information concerning
alcohol and tobacco habits and sexual behaviour.
Different authors found that HPV positive carcinoma
was associated with younger patients. Nasman et al
observed that patients with HPV positive tonsillar
cancer were younger than patients with HPV negative
cases (59 years versus 68 years) [6]. This trend was not
observed in our study.
Our study has limitations. First since the recruitment
was rather heterogeneous between centres and centres
were not evenly scattered on French territory despite
patients were recruited throughout France, the study
sample can not be considered as fully representative of
the French tonsil cancer population. Secondly, we used
DNA detection only; in this retrospective study it was
not possible to determine the presence of transcripts.
However, Nasman et al found that HPV 16 E6 or E7
RNA were expressed in the majority of the analysed
HPV 16 positive tumors [6]. Syrjanen et al found in
their review that HPV-16 E6 and E7 are actively tran-
scribed in most of the analysed tonsil carcinomas [16].
Hence, our results seems to be realistic even if we only
assessed DNA detection.
Conclusions
Our results indicate that HPV has a high prevalence in
tonsillar SCC. We emphasize the predominant role of
HPV 16 since 89% HPV-positive tumors were linked with
HPV 16; moreover 91% were associated with HPV 16
and/or 18. Unlike for cervical cancer, the association of
HPV and oncogenic mechanisms remain to be clarified.
These results are an indicator of the HPV distribution in
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tonsil cancers before HPV vaccine implementation
among women. The HPV vaccination of young women
will be able to contribute a posteriori to clarify the possi-
ble causal association between tonsil cancers and HPV.
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